Skip to main content
Signal8
Launch Terminal

Coherus Oncology, Inc. (CHRS)

Coherus Oncology, Inc. is a biopharmaceutical company primarily focused on the research, development, and commercialization of cancer immunotherapies across the United States. The company's commercialized products include several biosimilar therapies. These comprise UDENYCA, a long-acting granulocyte-colony stimulating factor biosimilar to Neulasta; YUSIMRY, an equivalent to Humira, prescribed for inflammatory conditions like rheumatoid arthritis, psoriasis, and Crohn's disease, which are characterized by heightened tumor necrosis factor (TNF) production; and CIMERLI, a Lucentis biosimilar aimed at treating specific ophthalmic disorders such as neovascular age-related macular degeneration, macular edema, and diabetic retinopathy. Beyond its commercial products, Coherus maintains a robust pipeline of investigational immunotherapies. This includes LOQTORZI, a novel, next-generation programmed death receptor-1 (PD-1) inhibitor; Casdozokitug, a recombinant human immunoglobulin G1 (IgG1) monoclonal antibody designed to target interleukin 27; CHS-114, a highly specific human afucosylated IgG1 monoclonal antibody targeting a chemokine receptor prevalent on Treg cells in the tumor microenvironment (TME); CHS-1000, an anti-ILT4 monoclonal antibody aimed at solid tumors; and GSK4381562, an antibody engineered to target CD112R on tumor cells. To support its endeavors, the company has forged several strategic alliances. These encompass a co-development and commercialization pact with Junshi Biosciences for toripalimab, as well as agreements with Surface and Adimab LLC. Its licensing portfolio includes arrangements with Bioeq AG, Genentech, Inc., Surface, and Vaccinex, Inc. Furthermore, Coherus has out-licensing agreements with Novartis Institutes for Biomedical Research, Inc. and GlaxoSmithKline Intellectual Property No. 4 Limited. Founded in 2010, the company currently operates as Coherus BioSciences, Inc., but is slated to officially rebrand as Coherus Oncology, Inc. in May 2025. Its headquarters are located in Redwood City, California.

Sector: Biological Products, (No Diagnostic Substances)

Industry: Biotechnology

Coherus Oncology, Inc. logo

Coherus Oncology, Inc.

NASDAQ:CHRSHealthcare
-7.60%$0.8301
AH$0.8420+1.43%vs close
Mkt Cap$128.25M
Float145.13M
O/S154.5M
Vol
$ Vol
RVOL
Inst Own45.3%
SI8.6%
Earnings
Dilution
Coherus Oncology, Inc. logoNASDAQ:CHRS$0.8301-7.60%
Upcoming Catalysts
  • tagmokitugREADOUT
    Cash runway at this date: 2mo
    Oct 28, 20265d ago8-K
Phase Distribution
18 lead-sponsored trials·4 active·9 completed
Phase 19
Phase 23
Phase 34
Phase 41
Not applicable1
(10 more as collaborator)

Trials need funding. See this company's dilution risk and cash position.

Clinical Trials
Sponsor role
Status
Phase
  • Phase 4
    Recruiting

    A Study of Toripalimab in Combination With Cisplatin and Gemcitabine in Participants With Recurrent Metastatic Nasopharyngeal Cancer

    Toripalimab, Cisplatin

    Nasopharyngeal Cancer Recurrent

    Enrollment
    100
    Start
    Nov 2024
    Primary Completion
    Dec 2027est.
    Completion
    Dec 2027est.
    NCT06457503
  • Phase 3
    Completed

    Comparison of CHS-0214 to Enbrel (Etanercept) in Patients With Rheumatoid Arthritis (RA)

    Etanercept, CHS-0214

    Rheumatoid Arthritis

    Enrollment
    647
    Start
    May 2014
    Primary Completion
    Oct 2015
    Completion
    May 2016
    NCT02115750
  • Phase 3
    Completed

    Comparison of CHS-0214 to Enbrel (Etanercept) in Patients With Chronic Plaque Psoriasis (PsO)

    Etanercept, CHS-0214

    Plaque Psoriasis

    Enrollment
    521
    Start
    Jun 2014
    Primary Completion
    Jul 2015
    Completion
    May 2016
    NCT02134210
  • Phase 3
    Completed

    A Long Term Safety Extension Study (CHS-0214-05)

    CHS-0214

    Rheumatoid Arthritis, Plaque Psoriasis

    Enrollment
    359
    Start
    Jul 2015
    Primary Completion
    Sep 2017
    Completion
    Oct 2017
    NCT02486939
  • Phase 3
    Completed

    Comparison of CHS-1420 Versus Humira in Subjects With Chronic Plaque Psoriasis

    CHS-1420, Adalimumab

    Plaque Psoriasis

    Enrollment
    545
    Start
    Aug 2015
    Primary Completion
    May 2016
    Completion
    Mar 2017
    NCT02489227
  • Phase 2
    Terminated

    Study of SRF617 With AB928 (Etrumadenant) and AB122 (Zimberelimab) in Patients With Metastatic Castration Resistant Prostate Cancer

    SRF617, etrumadenant

    Metastatic Castration-resistant Prostate Cancer, Prostate Cancer

    Enrollment
    16
    Start
    Jan 2022
    Primary Completion
    Apr 2023
    Completion
    Apr 2023
    NCT05177770
  • Phase 2
    Terminated

    Trial of Atezolizumab and Bevacizumab With CHS-388 or Placebo in Patients With Hepatocellular Carcinoma

    Casdozokitug, Atezolizumab

    Hepatocellular Carcinoma

    Enrollment
    30
    Start
    Apr 2022
    Primary Completion
    Jun 2025
    Completion
    Jul 2025
    NCT05359861
  • Phase 2
    Active, not recruiting

    A Trial of Casdozokitug in Combination With Toripalimab Plus Bevacizumab in Participants With Unresectable and/or Locally Advanced or Metastatic Hepatocellular Carcinoma

    Casdozokitug, Toripalimab

    Hepatocellular Carcinoma

    Enrollment
    72
    Start
    Dec 2024
    Primary Completion
    Sep 2027est.
    Completion
    Sep 2027est.
    NCT06679985
  • Phase 1
    Completed

    Comparison of the Pharmacokinetic and Pharmacodynamic Biosimilarity of CHS-1701 (Coherus Pegfilgrastim) With Neulasta® (Pegfilgrastim)

    CHS-1701, Pegfilgrastim

    Bioequivalence

    Enrollment
    116
    Start
    Feb 2015
    Primary Completion
    Jul 2015
    Completion
    Jul 2015
    NCT02385851
  • Phase 1
    Completed

    Assessing the Immunogenicity of 2 Subcutaneous Doses of CHS-1701 (Coherus Pegfilgrastim) With 2 Subcutaneous Doses Neulasta®

    CHS-1701, Pegfilgrastim (Neulasta)

    Immunity, Humoral

    Enrollment
    303
    Start
    May 2015
    Primary Completion
    Dec 2015
    Completion
    Dec 2015
    NCT02418104
  • Phase 1
    Completed

    Study to Assess the Pharmacokinetic and Pharmacodynamic Bioequivalence of CHS-1701 With Neulasta

    CHS-1701, Pegfilgrastim

    Healthy

    Enrollment
    122
    Start
    Feb 2016
    Primary Completion
    Jun 2016
    Completion
    Jun 2016
    NCT02650973
  • Phase 1
    Completed

    Study of SRF617 in Patients With Advanced Solid Tumors

    SRF617, Gemcitabine

    Advanced Solid Tumor

    Enrollment
    85
    Start
    Mar 2020
    Primary Completion
    Aug 2023
    Completion
    Aug 2023
    NCT04336098
  • Phase 1
    Completed

    Study of CHS-388 (Formerly Known as SRF388) in Patients With Advanced Solid Tumors

    CHS-388, Pembrolizumab

    Advanced Solid Tumor, Clear Cell Renal Cell Carcinoma +2

    Enrollment
    145
    Start
    Apr 2020
    Primary Completion
    May 2025
    Completion
    Jun 2025
    NCT04374877
  • Phase 1
    Active, not recruiting

    Study of CHS-114 in Participants With Advanced Solid Tumors

    CHS-114, toripalimab

    Advanced Solid Tumor, Head and Neck Squamous Cell Carcinoma

    Enrollment
    87
    Start
    Dec 2022
    Primary Completion
    Sep 2026est.
    Completion
    Jan 2027est.
    NCT05635643
  • Phase 1
    Terminated

    Study to Evaluate Safety and PK of CHS-006 in Combination With Toripalimab in Patients With Advanced Solid Tumors

    CHS-006 (anti-TIGIT), toripalimab (anti-PD-1)

    Advanced Solid Tumor, Non-Small Cell Lung Cancer +1

    Enrollment
    22
    Start
    Apr 2023
    Primary Completion
    Jul 2024
    Completion
    Jul 2024
    NCT05757492
  • Phase 1
    Not yet recruiting

    A Study of CHS-1000 in Participants With Advanced or Metastatic Solid Tumors

    CHS-1000, Toripalimab

    Advanced or Metastatic Solid Tumors

    Enrollment
    48
    Start
    Feb 2025est.
    Primary Completion
    May 2028est.
    Completion
    May 2028est.
    NCT06389526
  • Phase 1
    Recruiting

    A Study of CHS-114 (Tagmokitug) in Combination With Toripalimab and/or Other Treatments in Participants With Advanced Solid Tumors

    CHS-114, Toripalimab

    Metastatic Solid Tumor, Advanced Solid Tumor

    Enrollment
    154
    Start
    Apr 2025
    Primary Completion
    Jan 2028est.
    Completion
    Jan 2028est.
    NCT06657144
  • Observational
    Unknown status

    An Analysis to Estimate Febrile Neutropenia (FN) in Patients Receiving Udenyca

    Pegfilgrastim-Cbqv

    Febrile Neutropenia, Non-myeloid Malignancy

    Enrollment
    200
    Start
    Aug 2020
    Primary Completion
    Nov 2022est.
    Completion
    Dec 2022est.
    NCT04662892
Search ClinicalTrials.gov for “Coherus Oncology”